Astaxanthin as an Anticancer Agent against Breast Cancer: An In Vivo and In Vitro Investigation

Curr Med Chem. 2024 Apr 17. doi: 10.2174/0109298673288774240406053607. Online ahead of print.

Abstract

Aim: This study aimed to investigate the antioxidant properties, cytotoxic activity, and apoptotic effects of astaxanthin (ASX) on genes and pathways involved in breast cancer in Balb/c mice models injected with the 4T1 cell line.

Background: ASX could inhibit some tumor progression by using in vivo and in vitro models.

Objective: The effect of ASX on breast cancer was not fully understood till now.

Method: In an in vivo model, 4T1 cells-injected mice were administered with different concentrations of ASX (100 and 200 mg/kg), and histopathological evaluations were done using an optical microscope and the hematoxylin and eosin (H&E) staining. The real- time PCR investigated the expression levels of B-cell lymphoma 2-associated X (Bax), B-cell lymphoma 2 (Bcl-2), and Caspase 3 genes in mice treated with 100 and 200 mg/kg ASX. Also, the level of superoxide dismutase (SOD) and malondialdehyde (MDA) were examined in ASX-treated cancer mice.

Results: ASX (200 mg/kg) caused a significant reduction in the mitotic cell count of tumor tissues compared to ASX (100 mg/kg). The antiproliferative effects of different concentrations of ASX were shown based on the MTT results. The treatment of breast tumor mice with both concentrations of ASX, especially 200 mg/kg, elevated the expression of Caspase 3, Bax, and SOD enzyme levels and decreased Bcl-2 expression and MDA enzyme levels.

Conclusion: ASX can be considered a promising alternative treatment for breast cancer.

Keywords: Astaxanthin; apoptosis; breast cancer; cytotoxicity; in vitro.; in vivo; oxidative stress.